Revolutionizing the field of autoimmunity
RheumaGen is the only cell and gene therapy company editing the HLA gene to cure autoimmune diseases at their source.
Human Leukocyte Antigens (HLA) play a key role in the genetic origin of autoimmune diseases.
HLA cell markers help the immune system identify which cells are friends and which are foes to be eliminated. Autoimmune disease occurs when the body erroneously attacks its own healthy cells as if they were foreign invaders.
While other treatments seek to target inflammation and downstream symptoms, or to suppress the body’s immune response as a whole, RheumaGen is developing a unique, revolutionary technology that targets the HLA gene itself, using gene editing to turn off the genetic trigger causing the immune system to attack healthy cells.
